These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 17496166

  • 1. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [Abstract] [Full Text] [Related]

  • 2. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
    Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, Rokosz LL, Kaiser B, Li G, Wang W, Stauffer T, Ozgur L, Baldwin J, Taveras AG.
    J Med Chem; 2006 Dec 28; 49(26):7603-6. PubMed ID: 17181143
    [Abstract] [Full Text] [Related]

  • 4. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.
    Pulm Pharmacol Ther; 2015 Oct 28; 34():37-45. PubMed ID: 26271598
    [Abstract] [Full Text] [Related]

  • 5. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M, Singh D.
    J Pharmacol Exp Ther; 2013 Oct 28; 347(1):173-80. PubMed ID: 23912333
    [Abstract] [Full Text] [Related]

  • 6. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J, Struyf S, Wuyts A, Weyler M, Loos T, Gijsbers K, Gouwy M, Proost P, Van Damme J.
    Biochem Pharmacol; 2004 Nov 15; 68(10):1947-55. PubMed ID: 15476666
    [Abstract] [Full Text] [Related]

  • 7. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2.
    de Kruijf P, Lim HD, Overbeek SA, Zaman GJ, Kraneveld AD, Folkerts G, Leurs R, Smit MJ.
    Eur J Pharmacol; 2010 Sep 15; 643(1):29-33. PubMed ID: 20599927
    [Abstract] [Full Text] [Related]

  • 8. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.
    Int Immunopharmacol; 2012 Jul 15; 13(3):225-31. PubMed ID: 22561413
    [Abstract] [Full Text] [Related]

  • 9. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
    Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, Mallinder PR.
    Mol Pharmacol; 2008 Nov 15; 74(5):1193-202. PubMed ID: 18676678
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, Griswold DE, Martin L, Lee JM, White JR, Sarau HM.
    J Med Chem; 2004 Mar 11; 47(6):1319-21. PubMed ID: 14998320
    [Abstract] [Full Text] [Related]

  • 11. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
    Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, Galliera E, Di Benedetto P, Vigilante P, Bertini R, Allegretti M.
    J Med Chem; 2007 Aug 23; 50(17):3984-4002. PubMed ID: 17665889
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
    Yu Y, Dwyer MP, Chao J, Aki C, Chao J, Purakkattle B, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Qiu H, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, He Z, Lai G, Wu M, Taveras A.
    Bioorg Med Chem Lett; 2008 Feb 15; 18(4):1318-22. PubMed ID: 18242983
    [Abstract] [Full Text] [Related]

  • 13. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P, Taveras A, Yu Y, Zheng J, Chao J, Rindgen D, Jakway J, Hipkin RW, Fossetta J, Fan X, Fine J, Qiu H, Merritt JR, Baldwin JJ.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):228-31. PubMed ID: 18006311
    [Abstract] [Full Text] [Related]

  • 14. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P.
    Eur Cytokine Netw; 2006 Mar 01; 17(1):35-41. PubMed ID: 16613761
    [Abstract] [Full Text] [Related]

  • 15. CXCR2 inverse agonism detected by arrestin redistribution.
    Kredel S, Wolff M, Wiedenmann J, Moepps B, Nienhaus GU, Gierschik P, Kistler B, Heilker R.
    J Biomol Screen; 2009 Oct 01; 14(9):1076-91. PubMed ID: 19773589
    [Abstract] [Full Text] [Related]

  • 16. The activation of IL-8 receptors in cultured guinea pig Müller glial cells is modified by signals from retinal pigment epithelium.
    Malgorzata Goczalik I, Raap M, Weick M, Milenkovic I, Heidmann J, Enzmann V, Wiedemann P, Reichenbach A, Francke M.
    J Neuroimmunol; 2005 Apr 01; 161(1-2):49-60. PubMed ID: 15748943
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
    Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.
    J Pharmacol Exp Ther; 2015 May 01; 353(2):340-50. PubMed ID: 25736418
    [Abstract] [Full Text] [Related]

  • 18. Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2.
    Li F, Gordon JR.
    Biochem Biophys Res Commun; 2001 Aug 24; 286(3):595-600. PubMed ID: 11511101
    [Abstract] [Full Text] [Related]

  • 19. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P, Taveras AG, Dwyer MP, Yu Y, Chao J, Hipkin RW, Fan X, Rindgen D, Fine J, Lundell D.
    Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1431-3. PubMed ID: 19196511
    [Abstract] [Full Text] [Related]

  • 20. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.
    Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M.
    J Cell Biochem; 2007 May 01; 101(1):135-46. PubMed ID: 17295203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.